Oral leukoplakia is defined as a mucous membrane disorder characterized by white patches that cannot be scraped off. Leukoplakia is the most frequent, potentially premalignant oral mucosa disorder and a good candidate for chemopreventive therapies. Pioglitazone activates peroxisome proliferator–activated receptor gamma (PPARγ), which forms a complex with nuclear cofactors and regulates gene expression of a variety of cell-cycle proteins and is currently being tested preclinically and clinically in aerodigestive cancer prevention.
Methods:
In the present study, we hypothesized that pioglitazone would decrease proliferation of human leukoplakia cells (MSK Leuk1) and transformed bronchial epithelial cells (BEAS-2B) through regulatory changes of G1 checkpoint protein regulators, p21 and cyclin-D1. MSK Leuk1 and BEAS-2B cells were treated with pioglitazone and assayed for cell proliferation and p21 transcriptional activity.
Results:
We discovered pioglitazone significantly inhibited cell proliferation in a dose-dependent fashion. We also observed p21 protein induction after treatment with pioglitazone, which was preceded by measurable increases in p21 mRNA induction.
Conclusions:
We conclude the PPARγ activator, pioglitazone, can activate p21, which is associated with decreased proliferation in 2 aerodigestive preneoplastic cell lines. In addition, the p21 gene may be a potential hypothesis-driven biomarker in translational studies of pioglitazone as a chemoprevention agent for aerodigestive cancer.
American Cancer Society. Cancer facts & figures. Am Cancer Soc J. CA Cancer J Clin. 2018;68(1):7-30.
2.
HashibeMBrennanPChuangSCet al. Interaction between tobacco and alcohol use and the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. Cancer Epidemiol Biomarkers Prev. 2009;18(2):541-550.
3.
ChoiSYKahyoH.Effect of cigarette smoking and alcohol consumption in the aetiology of cancer of the oral cavity, pharynx and larynx. Int J Epidemiol. 1991;20(4):878-885.
4.
MehtaVYuGPSchantzSP.Population-based analysis of oral and oropharyngeal carcinoma: changing trends of histopathologic differentiation, survival and patient demographics. Laryngoscope. 2010;120(11):2203-2212.
5.
SilvermanS.Demographics and occurrence of oral and pharyngeal cancer: the outcomes, the trends, the challenge. J Am Dent Assoc. 2001;132:7S-11S.
6.
ArgirisAKaramouzisMVRabenDFerrisRL.Head and neck cancer. Lancet. 2008;371(9625):1695-1709.
7.
CarvalhoALNishimotoINCalifanoJAKowalskiLP.Trends in incidence and prognosis for head and neck cancer in the United States: a site-specific analysis of the SEER database. Int J Cancer. 2005;114(5):806-816.
8.
AmagasaTYamashiroMUzawaN.Oral premalignant lesions: from a clinical perspective. Int J Clin Oncol. 2011;16(1):5-14.
9.
KuribayashiYTsushimaFMoritaKIet al. Long-term outcome of non-surgical treatment in patients with oral leukoplakia. Oral Oncol. 2015;51(11):1020-1025.
10.
HolmstrupPVedtoftePReibelJStoltzeK.Long-term treatment outcome of oral premalignant lesions. Oral Oncol. 2006;42(5):461-474.
11.
HalderARaychowdhuryRGhoshADeM.Black tea (Camellia sinensis) as a chemopreventive agent in oral precancerous lesions. J Environ Pathol Toxicol Oncol. 2005;24(2):141-144.
12.
TsaoASLiuDMartinJet al. Phase II randomized, placebo-controlled trial of green tea extract in patients with high-risk oral premalignant lesions. Cancer Prev Res (Phila). 2009;2(11):931-941.
13.
NagaoTWarnakulasuriyaSNakamuraTet al. Treatment of oral leukoplakia with a low-dose of beta-carotene and vitamin C supplements: a randomized controlled trial. Int J Cancer. 2015;136(7):1708-1717.
14.
MallerySRTongMShumwayBSet al. Topical application of a mucoadhesive freeze-dried black raspberry gel induces clinical and histologic regression and reduces loss of heterozygosity events in premalignant oral intraepithelial lesions: results from a multicentered, placebo-controlled clinical trial. Clin Cancer Res. 2014;20(7):1910-1924.
15.
ChengALHsuCHLinJKet al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res. 2001;21(4B):2895-2900.
16.
ArmstrongWBTaylorTHKennedyARet al. Bowman birk inhibitor concentrate and oral leukoplakia: a randomized phase IIb trial. Cancer Prev Res (Phila). 2013;6(5):410-418.
17.
SabaNFHurwitzSJKonoSAet al. Chemoprevention of head and neck cancer with celecoxib and erlotinib: results of a phase ib and pharmacokinetic study. Cancer Prev Res (Phila). 2014;7(3):283-291.
18.
KadakiaSBadheyAMilamMLeeTDucicY.Topical oral cavity chemoprophylaxis using isotretinoin rinse: A 15-year experience. Laryngoscope. 2017;127(7):1595-1599.
19.
WilliamWNPapadimitrakopoulouVLeeJJet al. Erlotinib and the risk of oral cancer: the erlotinib prevention of oral cancer (EPOC) randomized clinical trial. JAMA Oncol. 2016;2(2):209-216.
20.
PapadimitrakopoulouVAWilliamWNJrDannenbergAJet al. Pilot randomized phase II study of celecoxib in oral premalignant lesions. Clin Cancer Res. 2008;14(7):2095-2101.
21.
GovindarajanRSimmonsDLLangNP.Thiazolidinedione (TZD) exposure and risk of squamous cell carcinoma of head and neck (SCCHN). 2007 ASCO Annual Meeting Proceedings Part I. J Clin Oncol. 2007;25(18 suppl):1511.
22.
MangelsdorfDJThummelCBeatoMet al. The nuclear receptor superfamily: the second decade. Cell. 1995;83(6):835-839.
23.
MichalikLDesvergneBWahliW.Peroxisome-proliferator-activated receptors and cancers: complex stories. Nat Rev Cancer. 2004;4(1):61-70.
24.
OndreyF.Peroxisome proliferator-activated receptor gamma pathway targeting in carcinogenesis: implications for chemoprevention. Clin Cancer Res. 2009;15(1):2-8.
25.
MangelsdorfDJEvansRM.The RXR heterodimers and orphan receptors. Cell. 1995;83(6):41-50.
26.
Yki-JärvinenH.Thiazolidinediones. N Engl J Med. 2004;351(11):1106-1118.
LehmannJMMooreLBSmith-OliverTAet al. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem. 1995;270(22):12953-12956.
29.
ApostoliAJRocheJMSchneiderMMet al. Opposing roles for mammary epithelial-specific PPARγ signaling and activation during breast tumour progression. Mol Cancer. 2015;14:85.
30.
ElstnerEMüllerCKoshizukaKet al. Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci U S A. 1998;95(15):8806-8811.
31.
ItamiAWatanabeGShimadaYet al. Ligands for peroxisome proliferator-activated receptor gamma inhibit growth of pancreatic cancers both in vitro and in vivo. Int J Cancer. 2001;94(3):370-376.
32.
NinomiyaIYamazakiKOyamaKet al. Pioglitazone inhibits the proliferation and metastasis of human pancreatic cancer cells. Oncol Lett. 2014;8(6):2709-2714.
33.
SawayamaHIshimotoTWatanabeMet al. Small molecule agonists of PPAR-γ exert therapeutic effects in esophageal cancer. Cancer Res. 2014;74(2):575-585.
34.
SarrafPMuellerEJonesDet al. Differentiation and reversal of malignant changes in colon cancer through PPARgamma. Nat Med. 1998;4(9):1046-1052.
35.
TsukaharaTHaniuH.Peroxisome proliferator-activated receptor gamma overexpression suppresses proliferation of human colon cancer cells. Biochem Biophys Res Commun. 2012;424(3):524-529.
36.
LylesBEAkinyekeTOMossPEStewartLV.Thiazolidinediones regulate expression of cell cycle proteins in human prostate cancer cells via PPARgamma-dependent and PPARgamma-independent pathways. Cell Cycle. 2009;8(2):268-277.
37.
KubotaTKoshizukaKWilliamsonEAet al. Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res. 1998;58(15):3344-3352.
BurottoMSzaboE.PPARγ in head and neck cancer prevention. Oral Oncol. 2014;50(10):924-929.
41.
HarperJWAdamiGRWeiNKeyomarsiKElledgeSJ.The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell. 1993;75(4):805-816.
42.
GartelALSerfasMSTynerAL.p21—negative regulator of the cell cycle. Proc Soc Exp Biol Med. 1996;213(2):138-149.
43.
OgryzkoVVWongPHowardBH.WAF1 retards S-phase progression primarily by inhibition of cyclin-dependent kinases. Mol Cell Biol. 1997;17(8):4877-4882.
44.
NiculescuABet al. Effects of p21(Cip1/Waf1) at both the G1/S and the G2/M cell cycle transitions: pRb is a critical determinant in blocking DNA replication and in preventing endoreduplication. Mol Cell Biol. 1998;18(1):629-643.
45.
RadhakrishnanSKFelicianoCSNajmabadiFet al. Constitutive expression of E2F-1 leads to p21-dependent cell cycle arrest in S phase of the cell cycle. Oncogene. 2004;23(23):4173-4176.
46.
BrugarolasJMobergKBoydSDTayaYJacksTLeesJA.Inhibition of cyclin-dependent kinase 2 by p21 is necessary for retinoblastoma protein-mediated G1 arrest after gamma-irradiation. Proc Natl Acad Sci U S A. 1999;96(3):1002-1007.
47.
HarperJWElledgeSJKeyomarsiKet al. Inhibition of cyclin-dependent kinases by p21. Mol Biol Cell. 1995;6(4):387-400.
48.
WagaSHannonGJBeachDStillmanB.The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature. 1994;369(6481):574-578.
49.
ShapiroGI.Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol. 2006;24(11):1770-1783.
50.
ChangTHSzaboE.Enhanced growth inhibition by combination differentiation therapy with ligands of peroxisome proliferator-activated receptor-gamma and inhibitors of histone deacetylase in adenocarcinoma of the lung. Clin Cancer Res. 2002;8(4):1206-1212.
51.
WrightSKWuertzBRHarrisGet al. Functional activation of PPARγ in human upper aerodigestive cancer cell lines. Mol Carcinog. 2017;56(1):149-162.
52.
WuertzBRDarrahLWudelJOndreyFG.Thiazolidinediones abrogate cervical cancer growth. Exp Cell Res. 2017;353(2):63-71.
53.
SeabloomDEGalbraithARHaynesAMet al. Safety and preclinical efficacy of aerosol pioglitazone on lung adenoma prevention in A/J mice. Cancer Prev Res (Phila). 2017;10(2):124-132.
54.
SeabloomDEGalbraithARHaynesAMet al. Fixed-dose combinations of pioglitazone and metformin for lung cancer prevention. Cancer Prev Res (Phila). 2017;10(2):116-123.
55.
RadhakrishnanSKGartelAL.The PPAR-gamma agonist pioglitazone post-transcriptionally induces p21 in PC3 prostate cancer but not in other cell lines. Cell Cycle. 2005;4(4):582-584.
56.
CoplandJAMarlowLAKurakataSet al. Novel high-affinity PPARgamma agonist alone and in combination with paclitaxel inhibits human anaplastic thyroid carcinoma tumor growth via p21WAF1/CIP1. Oncogene. 2006;25(16):2304-2317.
57.
LuDHanCWuT.15-PGDH inhibits hepatocellular carcinoma growth through 15-keto-PGE2/PPARγ-mediated activation of p21WAF1/Cip1. Oncogene. 2014;33(9):1101-1112.
58.
YinFWakinoSLiuZet al. Troglitazone inhibits growth of MCF-7 breast carcinoma cells by targeting G1 cell cycle regulators. Biochem Biophys Res Commun. 2001;286(5):916-922.
59.
FengZGuoWZhangCet al. CCND1 as a predictive biomarker of neoadjuvant chemotherapy in patients with locally advanced head and neck squamous cell carcinoma. PLoS One. 2011;6(10):e26399.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
